+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Vaso Occlusive Crisis Associated With Sickle Cell Disease R&D Pipeline Drugs and Companies

  • ID: 4745198
  • Report
  • January 2019
  • Region: Global
  • 75 Pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • ArQule, Inc.
  • AstraZeneca Plc
  • bluebird bio, Inc.
  • Imara Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • MORE

"2019 Future of Vaso Occlusive Crisis Associated With Sickle Cell Disease R&D Pipeline Drugs and Companies- Analysis of Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments"

The global demand for Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline companies from advancing their products into Phase 3 or Phase 4.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Report Description

The H1- 2019 pipeline review report on Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline compounds.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline guide presents information on all active drugs currently being developed for Vaso-Occlusive Crisis Associated With Sickle Cell Disease. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Vaso-Occlusive Crisis Associated With Sickle Cell Disease product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline report includes

  • An overview of Vaso-Occlusive Crisis Associated With Sickle Cell Disease disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of pipeline compounds
  • Company wise list of pipeline compounds
  • Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided

  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials

Reasons to Buy

  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into the market through in-depth strategic analysis review
  • Know the list of companies participating in global Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • ArQule, Inc.
  • AstraZeneca Plc
  • bluebird bio, Inc.
  • Imara Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. Executive Summary
3.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline, H1- 2019
3.5 Mechanism of Action wise Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Candidates

4. ArQule, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
4.1 ArQule, Inc. Business Profile
4.2 ArQule, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
4.2.1 Drug Snapshot
4.2.1.1 Originator
4.2.1.2 Collaborator/Co-Developer
4.2.1.3 Route of Administration
4.2.1.4 Orphan Drug/Fast Track/Special Designation
4.2.1.5 Area
4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
5.1 AstraZeneca Plc Business Profile
5.2 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
5.2.1 Drug Snapshot
5.2.1.1 Originator
5.2.1.2 Collaborator/Co-Developer
5.2.1.3 Route of Administration
5.2.1.4 Orphan Drug/Fast Track/Special Designation
5.2.1.5 Area
5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. bluebird bio, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
6.1 bluebird bio, Inc. Business Profile
6.2 bluebird bio, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
6.2.1 Drug Snapshot
6.2.1.1 Originator
6.2.1.2 Collaborator/Co-Developer
6.2.1.3 Route of Administration
6.2.1.4 Orphan Drug/Fast Track/Special Designation
6.2.1.5 Area
6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. Global Blood Therapeutics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
7.1 Global Blood Therapeutics Inc Business Profile
7.2 Global Blood Therapeutics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
7.2.1 Drug Snapshot
7.2.1.1 Originator
7.2.1.2 Collaborator/Co-Developer
7.2.1.3 Route of Administration
7.2.1.4 Orphan Drug/Fast Track/Special Designation
7.2.1.5 Area
7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
8.1 Hillhurst Biopharmaceuticals Inc Business Profile
8.2 Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
8.2.1 Drug Snapshot
8.2.1.1 Originator
8.2.1.2 Collaborator/Co-Developer
8.2.1.3 Route of Administration
8.2.1.4 Orphan Drug/Fast Track/Special Designation
8.2.1.5 Area
8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. Imara Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
9.1 Imara Inc Business Profile
9.2 Imara Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
9.2.1 Drug Snapshot
9.2.1.1 Originator
9.2.1.2 Collaborator/Co-Developer
9.2.1.3 Route of Administration
9.2.1.4 Orphan Drug/Fast Track/Special Designation
9.2.1.5 Area
9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
10.1 Modus Therapeutics Holding AB Business Profile
10.2 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
10.2.1 Drug Snapshot
10.2.1.1 Originator
10.2.1.2 Collaborator/Co-Developer
10.2.1.3 Route of Administration
10.2.1.4 Orphan Drug/Fast Track/Special Designation
10.2.1.5 Area
10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
11.1 Novartis AG Business Profile
11.2 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
11.2.1 Drug Snapshot
11.2.1.1 Originator
11.2.1.2 Collaborator/Co-Developer
11.2.1.3 Route of Administration
11.2.1.4 Orphan Drug/Fast Track/Special Designation
11.2.1.5 Area
11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
12.1 NuvOx Pharma LLC Business Profile
12.2 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
12.2.1 Drug Snapshot
12.2.1.1 Originator
12.2.1.2 Collaborator/Co-Developer
12.2.1.3 Route of Administration
12.2.1.4 Orphan Drug/Fast Track/Special Designation
12.2.1.5 Area
12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
13.1 Pfizer Inc Business Profile
13.2 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
13.2.1 Drug Snapshot
13.2.1.1 Originator
13.2.1.2 Collaborator/Co-Developer
13.2.1.3 Route of Administration
13.2.1.4 Orphan Drug/Fast Track/Special Designation
13.2.1.5 Area
13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
14.1 Prolong Pharmaceuticals LLC Business Profile
14.2 Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
14.2.1 Drug Snapshot
14.2.1.1 Originator
14.2.1.2 Collaborator/Co-Developer
14.2.1.3 Route of Administration
14.2.1.4 Orphan Drug/Fast Track/Special Designation
14.2.1.5 Area
14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. Sancilio & Company Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
15.1 Sancilio & Company Inc Business Profile
15.2 Sancilio & Company Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
15.2.1 Drug Snapshot
15.2.1.1 Originator
15.2.1.2 Collaborator/Co-Developer
15.2.1.3 Route of Administration
15.2.1.4 Orphan Drug/Fast Track/Special Designation
15.2.1.5 Area
15.2.1.6 Type of Molecular Entity
15.3 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16. Seattle Genetics, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
16.1 Seattle Genetics, Inc. Business Profile
16.2 Seattle Genetics, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
16.2.1 Drug Snapshot
16.2.1.1 Originator
16.2.1.2 Collaborator/Co-Developer
16.2.1.3 Route of Administration
16.2.1.4 Orphan Drug/Fast Track/Special Designation
16.2.1.5 Area
16.2.1.6 Type of Molecular Entity
16.3 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17. Selexys Pharmaceuticals Corporation Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Details
17.1 Selexys Pharmaceuticals Corporation Business Profile
17.2 Selexys Pharmaceuticals Corporation Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
17.2.1 Drug Snapshot
17.2.1.1 Originator
17.2.1.2 Collaborator/Co-Developer
17.2.1.3 Route of Administration
17.2.1.4 Orphan Drug/Fast Track/Special Designation
17.2.1.5 Area
17.2.1.6 Type of Molecular Entity
17.3 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18. Latest Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline Developments, 2019

19. Appendix
19.1 About Us
19.2 Sources and Methodology
19.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • ArQule, Inc.
  • AstraZeneca Plc
  • bluebird bio, Inc.
  • Global Blood Therapeutics Inc
  • Hillhurst Biopharmaceuticals Inc
  • Imara Inc
  • Modus Therapeutics Holding AB
  • Novartis AG
  • NuvOx Pharma LLC
  • Pfizer Inc
  • Prolong Pharmaceuticals LLC
  • Sancilio & Company Inc
  • Seattle Genetics, Inc.
  • Selexys Pharmaceuticals Corporation
Note: Product cover images may vary from those shown
Adroll
adroll